<DOC>
	<DOCNO>NCT02756351</DOCNO>
	<brief_summary>The study first step establish safety efficacy CytaCoat technology apply medical device nasal prong clinical data generate serve basis continuous study clinically significant setting neonatal care unit .</brief_summary>
	<brief_title>A Efficacy Safety Study Nasal Prongs With Proprietary Surface Coating Aiming Reduce Bacterial Colonization</brief_title>
	<detailed_description />
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Cross Infection</mesh_term>
	<mesh_term>Pneumonia , Ventilator-Associated</mesh_term>
	<criteria>1 . Legally competent , informed nature , scope relevance study , voluntarily agree participation study 's provision , duly sign informed consent form ( ICF ) . 2 . Subject 18 65 year age . 3 . Subjects intact , wound free scar free skin Nasal Prong target site . 4 . Subject intact , irritationfree nasal mucus membrane . 1 . Pregnant nursing woman . 2 . Subjects active smoker use snuff . 3 . Subjects currently suffer common cold , sinusitis , allergy sleep apnea . 4 . Subjects suffer and/or subject experience nosebleed within 1 month prior enter study . 5 . Subjects use and/or subject use oral topical antibiotic within 2 week prior enter study . 6 . Subjects use and/or subject use oral topical antiinflammatory drug within 1 week prior enter study . 7 . Subjects participate clinical study . 8 . Subjects diagnose type skin infection ( bacterial , viral fungal ) inflammatory skin disease include psoriasis , eczema severe acne 9 . Subjects diagnose type disease affect mucus membrane . 10 . Subjects suffer condition symptom prevent subject enter study , accord investigatorÂ´s judgment . 11 . Subjects lesion ( include lymphadenopathy ) , dysaesthesia , previous surgery abnormal anatomy Nasal Prong target site 12 . Any subject accord Declaration Helsinki deem unsuitable study enrolment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>